162 related articles for article (PubMed ID: 2453929)
1. [Treatment of benign prostatic hyperplasia with antiandrogens (cyproterone acetate) and antiestrogens (tamoxifen)].
Giovannoni S; Tassi B
Minerva Urol Nefrol; 1987; 39(4):363-8. PubMed ID: 2453929
[No Abstract] [Full Text] [Related]
2. [Current therapy of benign prostatic hypertrophy].
Rist M
Schweiz Rundsch Med Prax; 1986 Jul; 75(29):875-6. PubMed ID: 2426754
[No Abstract] [Full Text] [Related]
3. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
Petrangeli E; Sciarra F; Di Silverio F; Toscano V; Lubrano C; Conti C; Concolino G
J Steroid Biochem; 1988; 30(1-6):395-9. PubMed ID: 2455099
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of antiandrogens.
Namer M
J Steroid Biochem; 1988 Oct; 31(4B):719-29. PubMed ID: 2462132
[TBL] [Abstract][Full Text] [Related]
5. [Cyproterone acetate in benign prostatic hypertrophy].
Cocimano V; Marino G; Surleti D; Brigato R; Griffa D
Minerva Urol Nefrol; 1989; 41(4):275-6. PubMed ID: 2483594
[TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
Habenicht UF; Schröder H; el Etreby MF; Neumann F
Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
[No Abstract] [Full Text] [Related]
7. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
Bosch RJ; Griffiths DJ; Blom JH; Schroeder FH
J Urol; 1989 Jan; 141(1):68-72. PubMed ID: 2462067
[TBL] [Abstract][Full Text] [Related]
8. Local microwave hyperthermia and benign prostatic hyperplasia induced bladder outlet obstruction.
Rigatti P; Guzzoni G; Montorsi F
Adv Exp Med Biol; 1990; 267():433-7. PubMed ID: 1708192
[No Abstract] [Full Text] [Related]
9. [Indications of antiandrogens in benign hyperplasia of the prostate].
Benassayag E
J Urol (Paris); 1995; 101(2):109-10. PubMed ID: 8522854
[No Abstract] [Full Text] [Related]
10. [Treatment of hirsutism with peripherally acting antiandrogens. Experiences with cyproterone acetate].
Vinueza G; Zárate A; Canales ES
Ginecol Obstet Mex; 1980 Nov; 48(289):303-9. PubMed ID: 6454611
[No Abstract] [Full Text] [Related]
11. New forms and future perspectives in endocrine treatment of prostatic carcinoma.
Jacobi GH; Wenderoth UK
Prog Clin Biol Res; 1984; 153():529-45. PubMed ID: 6236463
[No Abstract] [Full Text] [Related]
12. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate.
Bartsch G; Daxenbichler G; Rohr HP
J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337
[TBL] [Abstract][Full Text] [Related]
13. Cyproterone acetate in the management of prostatic cancer.
Tunn UW
Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
[No Abstract] [Full Text] [Related]
14. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Tauveron I; Hermabessière J
Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
[No Abstract] [Full Text] [Related]
15. [Echotomographic evaluation of the recent endocrine trends in the treatment of so-called prostatic hypertrophy].
Napolitano A; Gargano E; Criniti P; Zezza A; Seccia M; Galfano G
Ann Ital Chir; 1983; 55(2):161-7. PubMed ID: 6197917
[No Abstract] [Full Text] [Related]
16. [Hirsutism treated with cyproterone acetate and ethinyl estradiol. Evaluation of the clinical effect].
Pedersen IM; Nielsen DR; Larsen J; Starup J
Ugeskr Laeger; 1985 Aug; 147(33):2594-6. PubMed ID: 2933858
[No Abstract] [Full Text] [Related]
17. [The sexual life of hirsute women treated with antiandrogens].
Raboch J; Stárka L; Raboch J
Cesk Gynekol; 1990 Sep; 55(8):596-8. PubMed ID: 2146036
[No Abstract] [Full Text] [Related]
18. [Antiandrogens in dermatological therapy. I. Mechanism of action of antiandrogens with special reference to the skin].
Zabel J
Przegl Dermatol; 1984; 71(3):291-5. PubMed ID: 6240670
[No Abstract] [Full Text] [Related]
19. [Indications and limits of anti-androgen therapy].
Zaun H
Z Hautkr; 1984 Aug; 59(16):1090-7. PubMed ID: 6207673
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity.
Schneider MR; Hartmann RW; Sinowatz F; Amselgruber W
J Cancer Res Clin Oncol; 1986; 112(3):258-65. PubMed ID: 2946698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
